Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) CEO Leonard S. Schleifer sold 9,064 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $1,015.43, for a total transaction of $9,203,857.52. Following the transaction, the chief executive officer now owns 55,134 shares […]
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) Director Michael S. Brown sold 1,172 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total value of $1,142,535.92. Following the completion of the sale, the director now directly owns […]
Insider Selling: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Insider Sells 16,848 Shares of Stock themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Regeneron Pharmaceuticals (NASDAQ:REGN) PT Raised to $1,030.00 theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price objective hoisted by TD Cowen from $1,020.00 to $1,030.00 in a report published on Wednesday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. A number of other analysts also recently commented on the stock. Truist Financial restated a buy rating […]